-
Most Popular
Search Results
240 results for CA
Broadcom Stock Tanks on CA Technologies Deal
Broadcom (AVGO) stock was falling hard on Thursday following news that it plans to acquire CA Technologies (CA) for $18.90 billion.
Trade of the Day: CA, Inc. (CA) Stock Programmed for More Gains
CA, Inc. has made some moves that Standard & Poor’s thinks should be good for continued growth — time to get into CA stock.
CA Technologies Is a Solid Long-Term Buy
CA Technologies reported stable if unimpressive earnings this week, but CA stock still looks set to deliver dependable long-term performance.
CA, Inc. (CA): Everyone Should Own This Unsexy Tech Stock
CA stock may not be the first name you think of in tech stocks, but with valuable IP assets, a large customer base and a…
3 Big Stock Charts for Thursday: CA, Inc. (CA), Autodesk, Inc. (ADSK) and Alexion Pharmaceuticals, Inc. (ALXN)
The resent spate of selling is claiming more casualties as shares of Autodesk (ADSK), Alexion (ALXN) and CA are all breaking through key technical trendlines.
How to Trade Broadcom Stock After CA Acquisition
The market doesn’t like Broadcom’s decision to buy CA for $18.9 billion. That was evident when AVGO stock was down 17% on Thursday.
Why Intrexon, LendingClub and CA Technologies Are 3 of Today’s Worst Stocks
Intrexon Corp., LendingClub Corporation and CA Technologies, Inc. used more than their fair share of red ink on Wednesday. Here’s the deal.
Look Anywhere but Acasti Pharma Stock for Opportunity
It doesn’t look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital. A dilutive equity raise would push…
Deep ‘Vs’ Spell Victory for CA Stock
These bullish formations usually precede a major advance.
Don’t Buy Broadcom Stock Until This Weird CA Acquisition Shakes Out
In a surprise move, Broadcom has agreed to acquire CA Technologies. It’s certainly puzzling, as there are little synergies. In fact, there could be some…
The Future Doesn’t Look Too Bright For Acasti Pharma Stock
Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed.
Toys R Us Store Closings 2018: See the Complete List of Locations
Toys R Us store closings 2018 are going to leave children with roughly 180 less stores to browse for their favorite toys.
The EU Crypto Vote Is In: Members Shoot Down MiCA Bill’s Proof of Work Ban
The EU crypto vote is finished, and crypto investors can breathe easily once again. Proof-of-work cryptos will not be banned in the EU.
Aurora Cannabis Stock May Fall Without Further Asset Sales
Aurora Cannabis recently sold marketable securities it owns. ACB stock may suffer unless more securities are sold to raise its liquidity.
Top 25 Area Codes Targeted for Cell Phone Spam
Here are Cloudmark’s top 25 area codes targeted for cell phone spam in the U.S.
Acasti Pharma Stock Is Bleeding Both Value and Credibility
Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests…
Buy Aphria Stock Before Its Price Catches up With Its Growth Prospects
Aphria stock valuation will benefit from its huge growth prospects next year. Recent guidance from Aphria suggests it will be hugely profitable. The valuation should…
Hexo Stock Is a Losing Bet So Investors Should Short It
Hexo stock is a losing bet. Hexo stock won’t survive without further capital, providing investors a great shorting opportunity.
Acasti Pharma Stock Could Soar Above $3 Soon
When Acasti posts Phase 3 trial results, ACST stock could re-visit recent highs. Here’s why you should pay attention to the stock now.
Adele Announces Tour for 2016: Concert Dates, Locations
Adele has officially announced her North American tour dates for 2016 and tickets for the concerts will go on sale this Thursday.
Here’s How Broadcom Stock Fell Back into Favor with Investors
Broadcom stock was practically un-ownable in July. With just a few words and the right results though, everything can change in an instant.
3 Bullish Earnings Plays
Three stocks that are set to report earnings are seeing great support at their 50-day trendlines, and could make very profitable short-term trades.
Acasti Pharma Stock Has One Last Chance
Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. TRILOGY 2 results in February mark the company’s last chance.
1 – 10 of 240 results
